Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Melbourne-based scientists have, for the first time, discovered how to "switch off" a molecule which is one of the top ...
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.
For patients with advanced prostate cancer (aPC), completion of a 12-week supervised exercise regimen leads to a significant ...
A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.
Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...
A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...
Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...
Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results